Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1420295

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1420295

Cutaneous Fibrosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America & Middle East & Africa)

PUBLISHED:
PAGES: 297 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PPT Slides/PDF & Excel (Enterprise License)
USD 4995

Add to Cart

Description

Table of Contents

The global cutaneous fibrosis treatment market, valued at US$ 600 million in 2024, is set to witness significant growth in the coming years. A comprehensive industry analysis suggests a projected Compound Annual Growth Rate (CAGR) of 9% for the next decade, indicating highly positive market expansion.

According to Fairfield Market Research, cutaneous fibrosis treatment solutions accounted for 12.6% of the global fibrotic disease treatment market in 2023, showcasing its growing importance in the healthcare landscape.

Cutaneous fibrosis, a condition for which there is currently no approved treatment, is part of a group of fibrotic diseases that represent significant unmet medical needs. As a result, the lack of approved medicines for these skin disorders presents a major revenue generation opportunity for drug manufacturers.

Key Opportunities for Cutaneous Fibrosis Drug Manufacturers:

  • Availability of Novel Treatment Options: With a substantial patient pool in both developed and developing countries, there is significant potential for revenue generation. Increasing awareness about cutaneous fibrosis treatment is expected to drive growth, particularly in developing regions.
  • Growing Diagnostics: Rising awareness about epidemiology, treatment approaches, and diagnostic tests worldwide is likely to boost the demand for cutaneous fibrosis treatment drugs, particularly in developing countries.

Challenges Hindering Market Growth:

  • Limited Treatment Options: Currently, drugs are the only form of symptomatic treatment for cutaneous fibrosis, which, while helpful, do not halt disease progression. This limitation can lead to reduced patient compliance and impact the overall quality of life.
  • Limited Awareness: Limited epidemiological data and awareness about cutaneous fibrosis, especially in developing countries, hinder the market's growth potential. This often results in untreated cases.
  • Lack of Novel Treatment Approaches: The absence of innovative treatment approaches makes effective treatment challenging, coupled with varying diagnosis stages and slow disease progression.

Country-wise Insights:

U.S. Market: North America, with the U.S. at the forefront, held a significant market share of in 2023. Frequent FDA approvals have led to increased product launches, making the U.S. a high revenue-generating country.

Germany: Germany accounted for 23.8% of the European cutaneous fibrosis treatment market in terms of value. The presence of large industry players in the country has contributed to its high market share.

China: China is emerging as a prominent market for cutaneous fibrosis treatment due to the development of medical infrastructure, strategic planning for expansion, and ongoing research activities. The country presents lucrative growth opportunities for market players.

Competitive Landscape:

Manufacturers of cutaneous fibrosis treatment drugs are actively seeking regulatory approvals and launching new products to strengthen their market positions. Key companies in this sector include:

  • Novartis AG
  • Pfizer
  • Sanofi
  • F. Hoffmann La Roche (Genetech, Inc.)
  • Boehringer Ingelheim International GmbH
  • Jubilant Cadista
  • Horizon Pharma USA, Inc.
  • Brotol-Myers Squibb Company
  • Teva Pharmaceuticals
  • Amgen
  • Johnson & Johnson Services

Key Segments Covered in Cutaneous Fibrosis Treatment Industry Research

Cutaneous Fibrosis Treatment Market by Drug Class:

  • Corticosteroids
  • Anti-fibrotic Drugs
  • Immunotherapy
  • Immunoglobulins

Cutaneous Fibrosis Treatment Market by Route of Administration:

  • Oral
  • Injectable
  • Topical

Cutaneous Fibrosis Treatment Market by Indication:

  • Keloid
  • Scleroderma
  • Radiation-induced Skin Fibrosis
  • Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis

Cutaneous Fibrosis Treatment Market by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Cutaneous Fibrosis Treatment Market by Region:

  • North America Cutaneous Fibrosis Treatment Market
  • Latin America Cutaneous Fibrosis Treatment
  • Europe Cutaneous Fibrosis Treatment
  • South Asia Cutaneous Fibrosis Treatment
  • East Asia Cutaneous Fibrosis Treatment
  • Oceania Cutaneous Fibrosis Treatment
  • Middle East & Africa (MEA) Cutaneous Fibrosis Treatment
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Cutaneous Fibrosis Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Cutaneous Fibrosis Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Cutaneous Fibrosis Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Corticosteroids
      • 3.1.1.2. Anti-fibrotic Drugs
      • 3.1.1.3. Immunotherapy
      • 3.1.1.4. Immunoglobulins
  • 3.2. Global Cutaneous Fibrosis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Oral
      • 3.2.1.2. Injectable
      • 3.2.1.3. Topical
  • 3.3. Global Cutaneous Fibrosis Treatment Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Keloid
      • 3.3.1.2. Scleroderma
      • 3.3.1.3. Radiation-induced Skin Fibrosis
      • 3.3.1.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
  • 3.4. Global Cutaneous Fibrosis Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. Hospital Pharmacies
      • 3.4.1.2. Retail Pharmacies
      • 3.4.1.3. Drug Stores
      • 3.4.1.4. Online Pharmacies
  • 3.5. Global Cutaneous Fibrosis Treatment Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Cutaneous Fibrosis Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Cutaneous Fibrosis Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Corticosteroids
      • 4.1.1.2. Anti-fibrotic Drugs
      • 4.1.1.3. Immunotherapy
      • 4.1.1.4. Immunoglobulins
  • 4.2. North America Cutaneous Fibrosis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Oral
      • 4.2.1.2. Injectable
      • 4.2.1.3. Topical
  • 4.3. North America Cutaneous Fibrosis Treatment Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Keloid
      • 4.3.1.2. Scleroderma
      • 4.3.1.3. Radiation-induced Skin Fibrosis
      • 4.3.1.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
  • 4.4. North America Cutaneous Fibrosis Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospital Pharmacies
      • 4.4.1.2. Retail Pharmacies
      • 4.4.1.3. Drug Stores
      • 4.4.1.4. Online Pharmacies
  • 4.5. North America Cutaneous Fibrosis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 4.5.1.2. U.S. Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 4.5.1.3. U.S. Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 4.5.1.4. U.S. Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 4.5.1.5. Canada Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 4.5.1.6. Canada Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 4.5.1.7. Canada Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 4.5.1.8. Canada Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Cutaneous Fibrosis Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Cutaneous Fibrosis Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Corticosteroids
      • 5.1.1.2. Anti-fibrotic Drugs
      • 5.1.1.3. Immunotherapy
      • 5.1.1.4. Immunoglobulins
  • 5.2. Europe Cutaneous Fibrosis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Oral
      • 5.2.1.2. Injectable
      • 5.2.1.3. Topical
  • 5.3. Europe Cutaneous Fibrosis Treatment Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Keloid
      • 5.3.1.2. Scleroderma
      • 5.3.1.3. Radiation-induced Skin Fibrosis
      • 5.3.1.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
  • 5.4. Europe Cutaneous Fibrosis Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospital Pharmacies
      • 5.4.1.2. Retail Pharmacies
      • 5.4.1.3. Drug Stores
      • 5.4.1.4. Online Pharmacies
  • 5.5. Europe Cutaneous Fibrosis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.2. Germany Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.3. Germany Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.5.1.4. Germany Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.5. U.K. Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.6. U.K. Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.7. U.K. Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.5.1.8. U.K. Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.9. France Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.10. France Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.11. France Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.5.1.12. France Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.13. Italy Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.14. Italy Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.15. Italy Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.5.1.16. Italy Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.17. Turkey Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.18. Turkey Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.19. Turkey Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.5.1.20. Turkey Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.21. Russia Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.22. Russia Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.23. Russia Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.5.1.24. Russia Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.25. Rest of Europe Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.26. Rest of Europe Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.27. Rest of Europe Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 5.5.1.28. Rest of Europe Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Cutaneous Fibrosis Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Cutaneous Fibrosis Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Corticosteroids
      • 6.1.1.2. Anti-fibrotic Drugs
      • 6.1.1.3. Immunotherapy
      • 6.1.1.4. Immunoglobulins
  • 6.2. Asia Pacific Cutaneous Fibrosis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Oral
      • 6.2.1.2. Injectable
      • 6.2.1.3. Topical
  • 6.3. Asia Pacific Cutaneous Fibrosis Treatment Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Keloid
      • 6.3.1.2. Scleroderma
      • 6.3.1.3. Radiation-induced Skin Fibrosis
      • 6.3.1.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
  • 6.4. Asia Pacific Cutaneous Fibrosis Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospital Pharmacies
      • 6.4.1.2. Retail Pharmacies
      • 6.4.1.3. Drug Stores
      • 6.4.1.4. Online Pharmacies
  • 6.5. Asia Pacific Cutaneous Fibrosis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.2. China Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.3. China Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.5.1.4. China Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.5. Japan Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.6. Japan Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.7. Japan Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.5.1.8. Japan Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.9. South Korea Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.10. South Korea Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.11. South Korea Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.5.1.12. South Korea Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.13. India Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.14. India Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.15. India Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.5.1.16. India Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.17. Southeast Asia Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.18. Southeast Asia Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.19. Southeast Asia Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.5.1.20. Southeast Asia Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.21. Rest of Asia Pacific Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.22. Rest of Asia Pacific Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.23. Rest of Asia Pacific Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 6.5.1.24. Rest of Asia Pacific Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Cutaneous Fibrosis Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Cutaneous Fibrosis Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Corticosteroids
      • 7.1.1.2. Anti-fibrotic Drugs
      • 7.1.1.3. Immunotherapy
      • 7.1.1.4. Immunoglobulins
  • 7.2. Latin America Cutaneous Fibrosis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Oral
      • 7.2.1.2. Injectable
      • 7.2.1.3. Topical
  • 7.3. Latin America Cutaneous Fibrosis Treatment Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Keloid
      • 7.3.1.2. Scleroderma
      • 7.3.1.3. Radiation-induced Skin Fibrosis
      • 7.3.1.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
  • 7.4. Latin America Cutaneous Fibrosis Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospital Pharmacies
      • 7.4.1.2. Retail Pharmacies
      • 7.4.1.3. Drug Stores
      • 7.4.1.4. Online Pharmacies
  • 7.5. Latin America Cutaneous Fibrosis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 7.5.1.2. Brazil Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.5.1.3. Brazil Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 7.5.1.4. Brazil Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.5.1.5. Mexico Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 7.5.1.6. Mexico Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.5.1.7. Mexico Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 7.5.1.8. Mexico Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.5.1.9. Argentina Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 7.5.1.10. Argentina Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.5.1.11. Argentina Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 7.5.1.12. Argentina Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.5.1.13. Rest of Latin America Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 7.5.1.14. Rest of Latin America Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.5.1.15. Rest of Latin America Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 7.5.1.16. Rest of Latin America Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Cutaneous Fibrosis Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Cutaneous Fibrosis Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Corticosteroids
      • 8.1.1.2. Anti-fibrotic Drugs
      • 8.1.1.3. Immunotherapy
      • 8.1.1.4. Immunoglobulins
  • 8.2. Middle East & Africa Cutaneous Fibrosis Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Oral
      • 8.2.1.2. Injectable
      • 8.2.1.3. Topical
  • 8.3. Middle East & Africa Cutaneous Fibrosis Treatment Market Outlook, by Indication, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Keloid
      • 8.3.1.2. Scleroderma
      • 8.3.1.3. Radiation-induced Skin Fibrosis
      • 8.3.1.4. Chronic Graft-versus-Host Disease (GvHD)-associated Cutaneous Fibrosis
  • 8.4. Middle East & Africa Cutaneous Fibrosis Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospital Pharmacies
      • 8.4.1.2. Retail Pharmacies
      • 8.4.1.3. Drug Stores
      • 8.4.1.4. Online Pharmacies
  • 8.5. Middle East & Africa Cutaneous Fibrosis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 8.5.1.2. GCC Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.3. GCC Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.5.1.4. GCC Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.5. South Africa Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 8.5.1.6. South Africa Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.7. South Africa Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.5.1.8. South Africa Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.9. Egypt Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 8.5.1.10. Egypt Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.11. Egypt Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.5.1.12. Egypt Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.13. Nigeria Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 8.5.1.14. Nigeria Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.15. Nigeria Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.5.1.16. Nigeria Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.17. Rest of Middle East & Africa Cutaneous Fibrosis Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 8.5.1.18. Rest of Middle East & Africa Cutaneous Fibrosis Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.19. Rest of Middle East & Africa Cutaneous Fibrosis Treatment Market by Indication, Value (US$ Mn), 2018 - 2031
      • 8.5.1.20. Rest of Middle East & Africa Cutaneous Fibrosis Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Product vs Indication Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Novartis AG
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Pfizer
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Sanofi
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. F. Hoffmann La Roche (Genetech, Inc.)
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Boehringer Ingelheim International GmbH
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Jubilant Cadista
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Horizon Pharma USA, Inc.
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Brotol-Myers Squibb Company
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Teva Pharmaceuticals
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Amgen
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!